Surgical Wound
Conditions
Keywords
Obstetrics, Gynecology, Wound healing
Brief summary
Study objective: The objective of this study is to evaluate through clinical criteria the clinical efficacy and safety of BCT Silver Bandage role in obstetrical and gynecological wound healing is as effective and safe as Aquacel® Ag. Dressing. Study devices: * Study device: BCT Silver Bandage * Comparator device:ConvaTecAquacel® Ag Hydrofiber Dressing Study design: * Randomized, Open-label, interventional, comparative, preventive study with Blinded evaluator. * All subjects must meet all the inclusion & exclusion criteria to enter this study in pre-operative phase. * Eligible subjects will be enrolled after a scheduled operative procedure. * There is SEVEN visits in this study (one screening eligibility phase up to 7 days before OP day, and four post-op treatment scheduled visits consisting on 1st , 3rd day, 5th day, 12th day and two follow up visit on the 28th and the 42nd post-operative day. * During each scheduled visit, each subject will have colored picture of his wound after dressing been removed, and on visit V6 for wound evaluation by blinded PI. Number of subjects: It is expected to recruit ≧150 eligible subjects. Study Duration: About eighteen month.
Interventions
DEVICEBCT Silver Bandage
Activated carbon fiber impregnated with silver particles
DEVICEAquacel® Ag. Dressing
Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.
Sponsors
Chung Shan Medical University
Bio-medical Carbon Technology Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Male/Female of any race aged between 18 - 70 years old * The subject is willing and able to understand, sign and date the study Informed Consent, and be able to adhere to the scheduled visits regimen. * The subject is having surgery (Cesarean pfannenstiel or Open Laparotomy incision) within 1 week
Exclusion criteria
* Patients with known allergy or topical hypersensitivity to ionic silver or alginate * Any systemic or local active dermatological disease that might interfere with the evaluation of the surgical site such as eczema, psoriasis, skin cancer, scleroderma, chronic urticarial * Patients undergoing MRI (Magnetic Resonance Imaging) examination. * Subject residence is outside the study center city * Patients was participating in another clinical trial less than 30 days before participation in this trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy measurements | 42 days after operation | 1. Wound infection rate within 5 days after operation 2. Wound healing evaluation by Stony Brook Scar Evaluation Scale (SBSES), to be evaluated by blinded PI at V6 3. Skin discoloration around the incision wound and/or wound keloid formation rate at V6 4. Patient and Observer Scar Assessment Scale (POSAS) on V3, V5 and V6 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety Measurement | 42 days after operation | The incidence of postoperative skin reactions (defined as blisters, itching, erythematous change around the surgical wound site) within 5 days after operation |
Countries
Taiwan
Outcome results
None listed